Fierce Health Payers January 10, 2022
Biogen’s decision to halve the price of its controversial Alzheimer’s drug Aduhelm has the Biden administration rethinking the 15% hike for Part B premiums for 2022.
Department of Health and Human Services Secretary Xavier Becerra announced Monday that he wants the Centers for Medicare and Medicaid Services to reassess its proposed price hike.
“With the 50% price drop of Aduhelm on January 1, there is a compelling basis for CMS to reexamine the previous recommendation,” Becerra said in a brief statement.
CMS announced in November that premiums for Part B for 2022 will increase from $148.50 to $170.10 and annual deductibles will also rise from $203 to $233.
Part B covers a slew of physician and hospital services and reimburses...